The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

Phase 2 Completed 30 enrolled Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab

RandomizedFactorialTriple-blindTreatment

Summary

The purpose of this study is to examine how medications thought to attenuate the effects of alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming drink, in non-treatment seeking alcohol-drinking daily smokers.

Timeline

Start: 2008-01
Primary completion: 2016-11
Completion: 2016-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naltrexone	Small molecule	25 mg	—
Subject	Varenicline	Small molecule	2 mg	—

Indications

No indication recorded.